Abstract
There is some evidence of retroviral infection in ALS. A randomized, double-blind, placebo-controlled trial of indinavir in ALS was performed to assess safety and efficacy trends. Nephrolithiasis and gastrointestinal side effects were frequent with indinavir treatment. Group differences in the rate of decline were not significant between the groups for the ALS Functional Rating Scale (p = 0.36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amyotrophic Lateral Sclerosis / drug therapy*
-
Amyotrophic Lateral Sclerosis / physiopathology
-
Amyotrophic Lateral Sclerosis / virology
-
Central Nervous System / drug effects*
-
Central Nervous System / physiopathology
-
Central Nervous System / virology
-
Double-Blind Method
-
Female
-
HIV Protease Inhibitors / administration & dosage
-
HIV Protease Inhibitors / adverse effects
-
Humans
-
Indinavir / administration & dosage*
-
Indinavir / adverse effects*
-
Kidney Calculi / chemically induced
-
Male
-
Middle Aged
-
Neuroprotective Agents / administration & dosage
-
Neuroprotective Agents / adverse effects
-
Pilot Projects
-
Placebos
-
Riluzole / administration & dosage
-
Riluzole / adverse effects
-
Treatment Failure
Substances
-
HIV Protease Inhibitors
-
Neuroprotective Agents
-
Placebos
-
Indinavir
-
Riluzole